German regulator expands probe into Gerresheimer books
German regulator BaFin expanded its probe into Gerresheimer to include 2025 half-yearly results. The audit examines lease liabilities and revenue recognition.
The financial regulator in Germany[Country:{"assets":{"country":"DE"}}], BaFin, has expanded its investigation into the financial statements of Gerresheimer AG[Symbol:{"assets":{"symbol":"GXI.DE"}}], the company announced on Wednesday. This development includes a new audit of the medical equipment maker’s 2025 half-yearly financial report, adding to a probe of its 2024 results that began earlier this month. The expanded investigation focuses on several critical accounting issues, including potential misstatements of lease liabilities and a failure to recognize impairments in the assets of the company’s Advanced Technologies unit. Additionally, the regulator is examining the 2025 half-yearly statement for outdated risk reporting, missing impairment charges, and irregularities in bill-and-hold revenue recognition, where income is recorded prior to the delivery of goods. Gerresheimer AG has stated that it expects the broadened accounting probe to affect its 2025 financial results. The company’s stock has struggled significantly, falling about 33% year-to-date following a 61% drop in 2025. That previous decline coincided with the exit of former CEO Dietmar Siemssen, who left the firm after a series of profit warnings. To address the situation, the company has hired a second auditing firm to review its accounting practices and revenue recognition for the 2024 and 2025 periods. Management noted that the results of this external review will likely impact the company’s financial outlook for 2025.
